NRx Pharmaceuticals (NASDAQ:NRXP) is a clinical‐stage biopharmaceutical company focused on the development and commercialization of repurposed and novel therapeutic candidates for diseases with high unmet medical need. Headquartered in New York, the company leverages established pharmacological compounds and patent‐protected formulations to accelerate development timelines and reduce clinical risk. Its research activities encompass neuropsychiatric disorders, inflammatory conditions and infectious disease‐related complications.
The company’s lead drug candidate, NRx‐101, is an oral fixed‐dose combination of D‐cycloserine and lurasidone in development for the treatment of bipolar depression with acute suicidal ideation or behavior. NRx‐101 has completed Phase II clinical trials and is advancing toward pivotal studies under protocols designed to meet FDA guidance for psychiatric indications. In parallel, NRx Pharmaceuticals is developing ifenprodil, an NMDA receptor antagonist licensed from Astellas Pharma, for use in respiratory distress syndromes, acute COVID-19 complications and long-term post‐viral inflammatory conditions.
NRx Pharmaceuticals operates on a model of drug repurposing and lifecycle management, in‐licensing compounds that have well‐characterized safety profiles and scaling them into new therapeutic areas. The company maintains strategic collaborations with academic medical centers and contract research organizations across North America and Europe to support its clinical programs. Its intellectual property portfolio includes composition of matter, new use and formulation patents, providing exclusivity for its lead products into the late 2030s.
The organization is led by a management team with extensive experience in pharmaceutical research, clinical operations and regulatory affairs. Senior leadership draws on backgrounds at multinational pharmaceutical companies, biotechnology startups and federal health agencies, guiding the company through clinical development milestones, regulatory interactions and strategic partnerships. NRx Pharmaceuticals continues to expand its pipeline and global footprint as it advances toward commercialization.
